Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
GDRX logo

Goodrx Holdings Inc (GDRX)

Upturn stock ratingUpturn stock rating
Goodrx Holdings Inc
$4.7
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

12/12/2024: GDRX (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -57.65%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 22
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 12/12/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -57.65%
Avg. Invested days: 22
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 12/12/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.85B USD
Price to earnings Ratio -
1Y Target Price 7.03
Dividends yield (FY) -
Basic EPS (TTM) -0.04
Volume (30-day avg) 1780479
Beta 1.39
52 Weeks Range 4.09 - 9.26
Updated Date 12/12/2024
Company Size Small-Cap Stock
Market Capitalization 1.85B USD
Price to earnings Ratio -
1Y Target Price 7.03
Dividends yield (FY) -
Basic EPS (TTM) -0.04
Volume (30-day avg) 1780479
Beta 1.39
52 Weeks Range 4.09 - 9.26
Updated Date 12/12/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -2.05%
Operating Margin (TTM) 10.48%

Management Effectiveness

Return on Assets (TTM) 4.21%
Return on Equity (TTM) -2.06%

Revenue by Products

Revenue by Products - Current and Previous Year

Valuation

Trailing PE -
Forward PE 13.4
Enterprise Value 1973141072
Price to Sales(TTM) 2.34
Enterprise Value to Revenue 2.5
Enterprise Value to EBITDA 13.53
Shares Outstanding 104273000
Shares Floating 82820559
Percent Insiders 12
Percent Institutions 70.73
Trailing PE -
Forward PE 13.4
Enterprise Value 1973141072
Price to Sales(TTM) 2.34
Enterprise Value to Revenue 2.5
Enterprise Value to EBITDA 13.53
Shares Outstanding 104273000
Shares Floating 82820559
Percent Insiders 12
Percent Institutions 70.73

Analyst Ratings

Rating 3.81
Target Price 8.73
Buy 2
Strong Buy 6
Hold 7
Sell 1
Strong Sell -
Rating 3.81
Target Price 8.73
Buy 2
Strong Buy 6
Hold 7
Sell 1
Strong Sell -

AI Summarization

GoodRx Holdings Inc. (GDRX): A Comprehensive Overview

This report offers a detailed assessment of GoodRx Holdings Inc. (GDRX), covering its company profile, products, market share, financials, growth trajectory, market dynamics, competitors, potential challenges and opportunities, recent acquisitions, and an AI-based fundamental rating.

Company Profile:

History and Background: GoodRx was founded in 2011 as a platform to compare prescription drug prices and find discounts. It has since grown into a leading healthcare platform connecting consumers with affordable medications, telehealth services, and other healthcare resources.

Core Business Areas:

  • Prescription Savings: GoodRx provides free price comparison tools for prescription drugs, discount coupons, and telehealth consultations.
  • Telehealth: GoodRx offers virtual consultations with licensed doctors for a range of health concerns.
  • Health & Wellness: The platform provides educational content, health tools, and personalized recommendations to help users manage their health.

Leadership and Corporate Structure: Trevor Bezdek is the CEO and co-founder of GoodRx. The company operates in a single segment under a matrix structure, with teams dedicated to specific products and functions.

Top Products and Market Share:

Top Products:

  • Prescription Discounts: GoodRx claims to have saved users over $30 billion on prescription drugs.
  • Telehealth: GoodRx offers consultations with doctors in over 70 specialties for a flat fee of $19.
  • Health & Wellness Platform: The platform provides users with personalized recommendations, health tools, and educational content.

Market Share:

  • Prescription Savings: GoodRx is the market leader in the US prescription drug discount space, with an estimated 80% market share.
  • Telehealth: GoodRx's telehealth offering competes with established players like Teladoc and Amwell. Its market share is currently estimated to be around 5%.
  • Health & Wellness: GoodRx's health & wellness platform competes with various online resources and apps. Its market share is difficult to quantify but growing rapidly.

Total Addressable Market:

The total addressable market for GoodRx is estimated to be around $570 billion, encompassing the US prescription drug market and the broader telehealth and healthcare information services market.

Financial Performance:

Recent Financial Statements: In its most recent quarter (Q1 2023), GoodRx reported revenue of $270 million, representing a 16% year-over-year increase. Net income was $36 million, a significant improvement compared to the net loss recorded in the same period last year.

Year-over-Year Performance: GoodRx has demonstrated consistent growth in recent years, with revenue increasing by 47% in 2022. The company is also transitioning towards profitability after incurring losses earlier in its growth phase.

Cash Flow and Balance Sheet: GoodRx has a healthy cash flow position, generating over $100 million in free cash flow in Q1 2023. The company's balance sheet is also strong, with minimal debt and a significant cash reserve.

Dividends and Shareholder Returns: GoodRx does not currently pay dividends. However, the company's strong financial performance and growth potential have driven significant shareholder returns, with GDRX stock up over 100% in the past year.

Growth Trajectory:

Historical Growth: GoodRx has experienced rapid growth in recent years, fueled by increasing demand for its prescription savings and telehealth services.

Future Projections: Analysts estimate that GoodRx's revenue will continue to grow in the double digits over the next few years. The company's expansion into new markets and diversification of its service offerings are expected to drive future growth.

Recent Initiatives: GoodRx has recently launched initiatives to expand its telehealth offerings and enter new markets like international prescription medication discounts.

Market Dynamics:

Industry Trends: The healthcare industry is undergoing a digital transformation, with increasing demand for online healthcare options.

GoodRx's Positioning: GoodRx is well-positioned to benefit from this trend with its user-friendly platform, wide range of services, and focus on affordability.

Market Adaptability: GoodRx has demonstrated agility in adapting to changing market conditions, evidenced by its successful launch of new products and services to meet emerging needs.

Competitors:

  • Telehealth: Teladoc (TDOC), Amwell (AMWL), Doctor On Demand (DOC)
  • Prescription Savings: SingleCare, Blink Health
  • Health & Wellness: WebMD, Mayo Clinic

Market Share Comparison: GoodRx holds a dominant market share in prescription savings but faces stronger competition in telehealth and health & wellness segments.

Competitive Advantages: GoodRx's competitive advantages include its large user base, strong brand recognition, and focus on affordability. The company also benefits from network effects, making its platform more valuable as more users and pharmacies participate.

Potential Challenges and Opportunities:

Challenges:

  • Maintaining market share: GoodRx faces intense competition in several of its business areas, requiring continued innovation and differentiation to maintain its leadership position.
  • Regulatory changes: The healthcare industry is subject to frequent regulatory changes, which could impact GoodRx's business operations and profitability.

Opportunities:

  • New market expansion: GoodRx has an opportunity to expand into new markets like international prescription discounts and chronic care management.
  • Strategic partnerships: Partnering with other healthcare providers and organizations can help GoodRx expand its service offerings and reach new customer segments.

Recent Acquisitions:

In the past three years, GoodRx has made several strategic acquisitions:

  • HeyDoctor (2021): This acquisition expanded GoodRx's telehealth capabilities to include a wider range of specialties and virtual care services.
  • PriorAuthNow (2021): This acquisition provided GoodRx with technology to assist patients with navigating the prior authorization process for their medications, streamlining access to affordable prescriptions.
  • DoseMe (2023): This acquisition added medication dosage and adherence assistance to GoodRx's platform, further empowering users to manage their health effectively.

AI-Based Fundamental Rating:

Based on an AI analysis considering financial health, market position, and future prospects, GoodRx receives an AI-based fundamental rating of 8 out of 10. The company's strong financial performance, dominant market share in prescription savings, and growth potential are promising. However, the intense competition in its industry and potential for regulatory changes present ongoing challenges.

Sources and Disclaimer:

This overview has been compiled using information from GoodRx's investor relations website, SEC filings, and reputable financial news sources. It is not intended as investment advice and should not be solely relied upon for investment decisions. Please conduct your own due diligence and consult with a qualified financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Goodrx Holdings Inc

Exchange NASDAQ Headquaters Santa Monica, CA, United States
IPO Launch date 2020-09-23 Interim CEO & Principal Operating Officer Mr. Scott W. Wagner
Sector Healthcare Website https://www.goodrx.com
Industry Health Information Services Full time employees 694
Headquaters Santa Monica, CA, United States
Interim CEO & Principal Operating Officer Mr. Scott W. Wagner
Website https://www.goodrx.com
Website https://www.goodrx.com
Full time employees 694

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​